Debanjan Ray, Synthekine CEO
Synthekine nabs $100M to boost IL-2 programs after rivals hit setbacks
Synthekine reeled in a $100 million financing to bankroll its IL-2 ambitions and get into the clinic with its first CAR-T.
The Series C fundraise …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
